Abstract: The present invention relates to a crystal type II of a compound represented by chemical formula 1, a method for preparing same, and a pharmaceutical composition including same. The crystal type II of the compound represented by chemical formula 1 of the present invention can be characterized by an XRD pattern, a DSC profile, and/or a TGA profile.
| # | Name | Date |
|---|---|---|
| 1 | 202317030837-TRANSLATIOIN OF PRIOIRTY DOCUMENTS ETC. [29-04-2023(online)].pdf | 2023-04-29 |
| 2 | 202317030837-STATEMENT OF UNDERTAKING (FORM 3) [29-04-2023(online)].pdf | 2023-04-29 |
| 3 | 202317030837-REQUEST FOR EXAMINATION (FORM-18) [29-04-2023(online)].pdf | 2023-04-29 |
| 4 | 202317030837-FORM 18 [29-04-2023(online)].pdf | 2023-04-29 |
| 5 | 202317030837-FORM 1 [29-04-2023(online)].pdf | 2023-04-29 |
| 6 | 202317030837-DRAWINGS [29-04-2023(online)].pdf | 2023-04-29 |
| 7 | 202317030837-DECLARATION OF INVENTORSHIP (FORM 5) [29-04-2023(online)].pdf | 2023-04-29 |
| 8 | 202317030837-COMPLETE SPECIFICATION [29-04-2023(online)].pdf | 2023-04-29 |
| 9 | 202317030837.pdf | 2023-05-03 |
| 10 | 202317030837-Proof of Right [26-05-2023(online)].pdf | 2023-05-26 |
| 11 | 202317030837-FORM-26 [24-07-2023(online)].pdf | 2023-07-24 |
| 12 | 202317030837-FORM 3 [04-10-2023(online)].pdf | 2023-10-04 |
| 13 | 202317030837-Certified Copy of Priority Document [10-10-2023(online)].pdf | 2023-10-10 |
| 14 | 202317030837-FER.pdf | 2025-03-11 |
| 15 | 202317030837-FORM 3 [14-05-2025(online)].pdf | 2025-05-14 |
| 16 | 202317030837-FORM 4 [05-09-2025(online)].pdf | 2025-09-05 |
| 1 | 202317030837_SearchStrategyNew_E_SearchHistoryE_03-03-2025.pdf |